Large Self-insured Employers Lack Power to Effectively Negotiate Hospital Prices
This study examines the ability of self-insured employers to negotiate hospital prices and the relationship between hospital prices and employer market power in the United States.
Payment Incentives and the Use of Higher-Cost Drugs: A Retrospective Cohort Analysis of Intravenous Iron in the Medicare Population
During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue.
Comparing Patient OOP Spending for Specialty Drugs in Medicare Part D and Employer-Sponsored Insurance
Out-of-pocket (OOP) spending for specialty drugs is substantially higher in Medicare Part D compared with employer-sponsored insurance because of the Part D benefit design.
Innovative Payment to Scale Up Access to Medications for Opioid Use Disorder
Bundled payments offer promise as a supplement to existing payment models to promote scaling up of opioid use disorder treatment using buprenorphine.
2 Clarke Drive Cranbury, NJ 08512